40
Participants
Start Date
January 12, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
omalizumab 300 mg every four weeks
"Continue standard treatment with omalizumab 300 mg every four weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12."
omalizumab 300 mg every six weeks
"Treatment in an extended interval of omalizumab 300 mg every six weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12."
RECRUITING
Department of Dermatology, Bispebjerg Hospital, Copenhagen
Aarhus University Hospital
OTHER
Simon Francis Thomsen
OTHER